Stockscreener 앱 받기
1.53
4.08%
-0.065
전일 마감가:
$1.595
열려 있는:
$1.6
하루 거래량:
496.09K
Relative Volume:
0.21
시가총액:
$16.27M
수익:
-
순이익/손실:
$-39.14M
주가수익비율:
-0.2563
EPS:
-5.97
순현금흐름:
$-28.20M
1주 성능:
-1.92%
1개월 성능:
+67.65%
6개월 성능:
-53.64%
1년 성능:
-92.60%
1일 변동 폭
$1.5201
$1.67
1주일 범위
$1.42
$1.81
52주 변동 폭
$0.65
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
명칭
Citius Pharmaceuticals Inc
전화
(908) 967-6676
주소
11 COMMERCE DRIVE, CRANFORD, NJ
CTXR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.53 | 17.43M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
Citius Pharmaceuticals Inc. Stock Analysis and ForecastFree Technical Analysis Support - Autocar Professional
Citius Oncology Announces Closing of $9.0 Million Public Offering - Eastern Progress
What analysts say about Citius Pharmaceuticals Inc. stockTremendous return on equity - Autocar Professional
Is Citius Pharmaceuticals Inc. a good long term investmentFree Market Volatility Navigation Tips - Jammu Links News
What drives Citius Pharmaceuticals Inc. stock priceRobust investment performance - Jammu Links News
Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia
Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest
Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛
Cencora distribution deal boosts Citius shares - MSN
Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest
Citius Oncology Announces Pricing of $9.0 Million Public Offering - Benzinga
Citius Oncology Announces Pricing of $9.0 Million Public Offering - The Malaysian Reserve
Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest
Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha
Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus
Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com Nigeria
Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com
Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener
Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha
Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com Nigeria
Pre-market Movers: KAPA, CYCC, SONN, RANI... - RTTNews
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - PR Newswire
Citius Pharmaceuticals Soars 10.18% on Nasdaq Compliance - AInvest
Citius Pharmaceuticals' Strategic Financing: Balancing Dilution Risks with LYMPHIR's Commercial Potential - AInvest
Citius Oncology Plans Stock Offering; Shares Down - MarketScreener
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) On The Verge Of Breaking Even - simplywall.st
Citius Pharmaceuticals regains Nasdaq compliance - MSN
Citius Pharmaceuticals Regains Nasdaq Compliance - The Globe and Mail
CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Citius Pharmaceuticals regains Nasdaq compliance after 10-day streak - Investing.com
Citius Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement - 富途牛牛
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - Finansavisen
Citius Pharmaceuticals: LYMPHIR Launch Ignites High-Growth Potential in CTCL Market - AInvest
Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR - Insider Monkey
Citius Pharmaceuticals (CTXR) Receives Buy Rating from Analyst | CTXR Stock News - GuruFocus
Is Citius Pharmaceuticals, Inc. technically bullish or bearish? - MarketsMojo
Pre-market Movers: INDP, IBO, CDTX, FBRX... - RTTNews
Citius Oncology prepares for lymphoma treatment launch in 2025 By Investing.com - Investing.com Nigeria
Citius Oncology On Track to Launch Lymphir in US in H2 - MarketScreener
Citius Oncology prepares for lymphoma treatment launch in 2025 - Investing.com
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 - PR Newswire
Millennium Management LLC Sells 1,126,188 Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - The Victoria Advocate
Citius Pharmaceuticals Closes $6M Securities Offering - TipRanks
After Major Oncology Conference, All Eyes Turn to Industry Innovation - Quantisnow
Citius Pharmaceuticals Announces Closing Of Registered Direct Offering Of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - MarketScreener
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits - Quantisnow
Citius Pharmaceuticals Secures $15.8M Financing Deal: What This Means for LYMPHIR Commercialization - Stock Titan
Citius Pharmaceuticals Inc (CTXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
0.34%
자본화:
|
볼륨(24시간):